Ezh2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Ezh2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) Rattus norvegicus
Analyze
Symbol: Ezh2
Name: enhancer of zeste 2 polycomb repressive complex 2 subunit
RGD ID: 1595860
Description: Enables chromatin binding activity and transcription cis-regulatory region binding activity. Involved in several processes, including GABAergic synaptic transmission; negative regulation of macromolecule metabolic process; and positive regulation of dendrite development. Located in cytoplasm and nucleus. Used to study endometriosis. Biomarker of leiomyoma; non-alcoholic fatty liver disease; and pancreatic cancer. Human ortholog(s) of this gene implicated in several diseases, including Weaver syndrome; gastrointestinal system cancer (multiple); glioblastoma; hematologic cancer (multiple); and osteosarcoma. Orthologous to human EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit); PARTICIPATES IN histone modification pathway; methionine cycle/metabolic pathway; INTERACTS WITH 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: enhancer of zeste 2; enhancer of zeste homolog 2; enhancer of zeste homolog 2 (Drosophila); histone-lysine N-methyltransferase EZH2; LOC312299; MGC189404; similar to Enhancer of zeste homolog 2 (ENX-1)
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2476,624,399 - 76,687,362 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl476,624,399 - 76,687,362 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx481,590,638 - 81,653,503 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0477,503,983 - 77,566,865 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0475,884,156 - 75,947,036 (-)NCBIRnor_WKY
Rnor_6.0477,284,404 - 77,347,011 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl477,284,404 - 77,347,011 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.04141,955,864 - 142,018,471 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4475,709,959 - 75,773,279 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera471,429,142 - 71,492,047 (-)NCBICelera
Cytogenetic Map4q24NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISS)
acute megakaryocytic leukemia  (ISO)
acute myeloid leukemia  (ISO)
B-cell lymphoma  (ISO,ISS)
Breast Neoplasms  (ISO)
cholangiocarcinoma  (ISO)
Chromosome Breakage  (ISO)
chronic myeloid leukemia  (ISO)
chronic myelomonocytic leukemia  (ISO)
colon cancer  (ISO)
colorectal adenocarcinoma  (ISO)
colorectal adenoma  (ISO)
colorectal cancer  (ISO)
colorectal carcinoma  (ISO)
Congenital Upper Extremity Deformities  (ISO)
congestive heart failure  (ISO)
cortical dysplasia-focal epilepsy syndrome  (ISO)
COVID-19  (ISO)
craniosynostosis  (ISO)
diffuse large B-cell lymphoma  (ISO)
Endometrial Neoplasms  (ISO)
endometriosis  (IMP)
esophagus squamous cell carcinoma  (ISO)
Experimental Colitis  (ISO)
Experimental Diabetes Mellitus  (IEP)
follicular lymphoma  (ISO)
genetic disease  (ISO)
glioblastoma  (ISO)
hepatocellular carcinoma  (ISO)
invasive ductal carcinoma  (ISO)
juvenile myelomonocytic leukemia  (ISO)
Kidney Reperfusion Injury  (ISO)
Left Ventricular Hypertrophy  (IEP)
leiomyoma  (IEP)
lung adenocarcinoma  (ISO)
lung cancer  (ISO)
lung non-small cell carcinoma  (ISO)
lymphoma  (ISO)
malignant pleural mesothelioma  (ISO)
myelodysplastic syndrome  (ISO)
myelodysplastic/myeloproliferative neoplasm  (ISO)
myelofibrosis  (ISO)
myeloid leukemia associated with Down Syndrome  (ISO)
myeloid neoplasm  (ISO)
nasopharynx carcinoma  (ISO)
Neoplasm Metastasis  (ISO)
Neoplastic Cell Transformation  (ISO)
Neurodevelopmental Disorders  (ISO)
non-alcoholic fatty liver disease  (IEP)
non-Hodgkin lymphoma  (ISO)
oral squamous cell carcinoma  (ISO)
osteosarcoma  (ISO)
pancreatic cancer  (IEP)
Peritoneal Adhesions  (IEP)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
renal Wilms' tumor  (ISO)
skin melanoma  (ISO)
stomach cancer  (ISO)
T-cell acute lymphoblastic leukemia  (ISO)
Transplant Rejection  (IMP)
urinary bladder cancer  (ISO)
Weaver syndrome  (ISO)
Weight Gain  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-Eudesmin  (ISO)
1,1-dichloroethene  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-methylcholine  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
8-Br-cAMP  (ISO)
acrylamide  (EXP)
aflatoxin B1  (ISO)
Aflatoxin B2 alpha  (ISO)
all-trans-retinoic acid  (ISO)
allethrin  (EXP)
andrographolide  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
aristolochic acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
azathioprine  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzo[e]pyrene  (ISO)
bisphenol A  (EXP,ISO)
buta-1,3-diene  (ISO)
cadmium dichloride  (ISO)
calcitriol  (ISO)
carbon nanotube  (ISO)
carmustine  (ISO)
CGP 52608  (ISO)
chlordecone  (ISO)
cisplatin  (ISO)
clorgyline  (ISO)
clothianidin  (ISO)
cobalt dichloride  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
corticosterone  (EXP)
coumarin  (ISO)
coumestrol  (ISO)
Cuprizon  (EXP)
cyclosporin A  (ISO)
cyhalothrin  (EXP)
cypermethrin  (EXP)
dexamethasone  (ISO)
diarsenic trioxide  (ISO)
dibutyl phthalate  (EXP,ISO)
diethylstilbestrol  (EXP,ISO)
dioxygen  (ISO)
doxorubicin  (ISO)
endosulfan  (EXP,ISO)
Enterolactone  (ISO)
enzalutamide  (ISO)
ethanol  (ISO)
fenvalerate  (EXP)
formaldehyde  (ISO)
genistein  (EXP)
geraniol  (ISO)
glycerol 2-phosphate  (ISO)
GSK343  (ISO)
heptachlor  (EXP)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
ibuprofen  (EXP)
ketamine  (EXP)
L-ascorbic acid  (ISO)
lead(0)  (EXP,ISO)
lead(2+)  (EXP,ISO)
lipopolysaccharide  (ISO)
lucanthone  (ISO)
medroxyprogesterone acetate  (ISO)
menadione  (ISO)
methapyrilene  (ISO)
methotrexate  (ISO)
methyl methanesulfonate  (ISO)
methylazoxymethanol  (ISO)
morphine  (EXP,ISO)
myo-inositol hexakisphosphate  (ISO)
N-acetyl-L-cysteine  (ISO)
N-nitrosodiethylamine  (ISO)
oxaliplatin  (EXP)
ozone  (ISO)
palbociclib  (ISO)
paracetamol  (EXP,ISO)
PCB138  (ISO)
pentachlorophenol  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
piroxicam  (ISO)
potassium dichromate  (ISO)
progesterone  (ISO)
quercetin  (ISO)
resveratrol  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (EXP)
Soman  (EXP)
stattic  (ISO)
streptozocin  (ISO)
sunitinib  (ISO)
tamoxifen  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (ISO)
tetrachloromethane  (ISO)
thioacetamide  (EXP)
topotecan  (EXP,ISO)
Tributyltin oxide  (ISO)
trichloroethene  (EXP)
trimellitic anhydride  (ISO)
Triptolide  (ISO)
triptonide  (ISO)
troglitazone  (ISO)
trovafloxacin  (ISO)
urethane  (ISO)
valproic acid  (ISO)
vemurafenib  (ISO)
vorinostat  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
B cell differentiation  (ISO)
cardiac muscle hypertrophy in response to stress  (ISO)
cell development  (ISO)
cellular response to hydrogen peroxide  (ISO)
cellular response to trichostatin A  (ISO)
cerebellar cortex development  (ISO)
DNA methylation  (ISO)
epidermal cell differentiation  (ISO)
facultative heterochromatin formation  (ISO)
G1 to G0 transition  (ISO)
G1/S transition of mitotic cell cycle  (ISO)
hemopoiesis  (ISO)
hepatocyte homeostasis  (ISO)
heterochromatin formation  (IBA)
hippocampus development  (IEP)
histone H3-K27 methylation  (ISO)
histone H3-K27 trimethylation  (IBA,ISO)
histone methylation  (ISO)
histone modification  (IMP)
keratinocyte differentiation  (ISO)
liver regeneration  (ISO)
negative regulation of cytokine production involved in inflammatory response  (IMP)
negative regulation of DNA-binding transcription factor activity  (ISO)
negative regulation of DNA-templated transcription  (ISO)
negative regulation of epidermal cell differentiation  (ISO)
negative regulation of G1/S transition of mitotic cell cycle  (ISO)
negative regulation of gene expression  (IMP)
negative regulation of gene expression, epigenetic  (ISO)
negative regulation of keratinocyte differentiation  (ISO)
negative regulation of retinoic acid receptor signaling pathway  (ISO)
negative regulation of stem cell differentiation  (ISO)
negative regulation of striated muscle cell differentiation  (ISO)
negative regulation of transcription by RNA polymerase II  (IMP,ISO)
negative regulation of transcription elongation by RNA polymerase II  (ISO)
positive regulation of cell cycle G1/S phase transition  (ISO)
positive regulation of cell population proliferation  (ISO)
positive regulation of dendrite development  (IMP)
positive regulation of epithelial to mesenchymal transition  (ISO)
positive regulation of GTPase activity  (ISO)
positive regulation of MAP kinase activity  (ISO)
positive regulation of protein serine/threonine kinase activity  (ISO)
protein localization to chromatin  (ISO)
regulation of cell population proliferation  (ISO)
regulation of circadian rhythm  (ISO)
regulation of gene expression  (ISO)
regulation of gliogenesis  (ISO)
regulation of kidney development  (IEP)
regulation of neurogenesis  (ISO)
regulation of protein phosphorylation  (ISO)
regulation of transcription by RNA polymerase II  (ISO)
response to estradiol  (IEP)
response to tetrachloromethane  (ISO)
rhythmic process  (IEA)
skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration  (ISO)
stem cell differentiation  (ISO)
subtelomeric heterochromatin formation  (ISO)
synaptic transmission, GABAergic  (IMP)

Cellular Component

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Modified Adenovirus Reduces De Novo Peritoneal Adhesions in Rats and Limits Off-Target Transfection. Role of EZH2 in Adhesion Formation. Atta HM, etal., J Invest Surg. 2017 Apr;30(2):78-87. doi: 10.1080/08941939.2016.1229366. Epub 2016 Oct 3.
2. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Behrens C, etal., Clin Cancer Res. 2013 Dec 1;19(23):6556-65. doi: 10.1158/1078-0432.CCR-12-3946. Epub 2013 Oct 4.
3. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Bejar R, etal., J Clin Oncol. 2012 Sep 20;30(27):3376-82. doi: 10.1200/JCO.2011.40.7379. Epub 2012 Aug 6.
4. Histone Methyltransferase EZH2 Is Transcriptionally Induced by Estradiol as Well as Estrogenic Endocrine Disruptors Bisphenol-A and Diethylstilbestrol. Bhan A, etal., J Mol Biol. 2014 Oct 9;426(20):3426-41. doi: 10.1016/j.jmb.2014.07.025. Epub 2014 Aug 1.
5. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Black JC, etal., Mol Cell. 2012 Nov 30;48(4):491-507. doi: 10.1016/j.molcel.2012.11.006.
6. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Bracken AP, etal., EMBO J. 2003 Oct 15;22(20):5323-35.
7. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cao W, etal., Cancer Prev Res (Phila). 2011 Nov;4(11):1816-24. doi: 10.1158/1940-6207.CAPR-11-0130. Epub 2011 Jun 22.
8. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. Cao W, etal., PLoS One. 2012;7(12):e52984. doi: 10.1371/journal.pone.0052984. Epub 2012 Dec 31.
9. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. Choi JH, etal., APMIS. 2010 Mar;118(3):196-202. doi: 10.1111/j.1600-0463.2009.02579.x.
10. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Crea F, etal., Ann Oncol. 2012 May;23(5):1207-1213. doi: 10.1093/annonc/mdr387. Epub 2011 Sep 16.
11. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Fluge Ø, etal., Br J Cancer. 2009 Oct 20;101(8):1282-9. doi: 10.1038/sj.bjc.6605333. Epub 2009 Sep 22.
12. RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Fujii S, etal., Biochem Biophys Res Commun. 2012 Jan 20;417(3):1074-9. doi: 10.1016/j.bbrc.2011.12.099. Epub 2011 Dec 26.
13. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
14. Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. Greathouse KL, etal., Mol Cancer Res. 2012 Apr;10(4):546-57. doi: 10.1158/1541-7786.MCR-11-0605.
15. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Grossmann V, etal., Leukemia. 2011 May;25(5):877-9. doi: 10.1038/leu.2011.10. Epub 2011 Feb 22.
16. EZH2 mutational status predicts poor survival in myelofibrosis. Guglielmelli P, etal., Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.
17. Targeting protein lysine methylation and demethylation in cancers. He Y, etal., Acta Biochim Biophys Sin (Shanghai). 2012 Jan;44(1):70-9. doi: 10.1093/abbs/gmr109.
18. Histone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiation. Heinen A, etal., Glia. 2012 Nov;60(11):1696-708. doi: 10.1002/glia.22388. Epub 2012 Jul 20.
19. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons. Henriquez B, etal., Mol Cell Neurosci. 2013 Nov;57:130-43. doi: 10.1016/j.mcn.2013.07.012. Epub 2013 Aug 8.
20. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Herrera-Merchan A, etal., Nat Commun. 2012 Jan 10;3:623. doi: 10.1038/ncomms1623.
21. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Herz HM, etal., Trends Biochem Sci. 2013 Dec;38(12):621-39. doi: 10.1016/j.tibs.2013.09.004. Epub 2013 Oct 20.
22. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth. Hwang CF, etal., Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):597-604. doi: 10.1016/j.ijrobp.2010.11.062. Epub 2011 Feb 6.
23. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Kemp CD, etal., Clin Cancer Res. 2012 Jan 1;18(1):77-90. doi: 10.1158/1078-0432.CCR-11-0962. Epub 2011 Oct 25.
24. Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality. Kiefer KC, etal., ESC Heart Fail. 2021 Jun;8(3):1873-1884. doi: 10.1002/ehf2.13297. Epub 2021 Mar 28.
25. Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes. Komers R, etal., Lab Invest. 2013 May;93(5):543-52. doi: 10.1038/labinvest.2013.47. Epub 2013 Mar 18.
26. The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway. Kurihara H, etal., Oncotarget. 2016 Mar 15;7(11):12704-17. doi: 10.18632/oncotarget.7260.
27. Polycomb repressive complex 2 (PRC2) suppresses Emu-myc lymphoma. Lee SC, etal., Blood. 2013 Oct 10;122(15):2654-63. doi: 10.1182/blood-2013-02-484055. Epub 2013 Aug 27.
28. Inhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in rats. Li L, etal., BMC Immunol. 2016 Oct 26;17(1):41. doi: 10.1186/s12865-016-0179-3.
29. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features. Liu Y, etal., Hum Pathol. 2017 Jun;64:213-221. doi: 10.1016/j.humpath.2017.04.011. Epub 2017 Apr 22.
30. Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma. Lu B, etal., ACS Med Chem Lett. 2018 Jan 29;9(2):98-102. doi: 10.1021/acsmedchemlett.7b00437. eCollection 2018 Feb 8.
31. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma. Lv YF, etal., Sci Rep. 2015 Aug 12;5:12999. doi: 10.1038/srep12999.
32. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Matsukawa Y, etal., Cancer Sci. 2006 Jun;97(6):484-91. doi: 10.1111/j.1349-7006.2006.00203.x.
33. Accumulation of malignant renal stem cells is associated with epigenetic changes in normal renal progenitor genes. Metsuyanim S, etal., Stem Cells. 2008 Jul;26(7):1808-17. doi: 10.1634/stemcells.2007-0322. Epub 2008 May 8.
34. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. Muto T, etal., J Exp Med. 2013 Nov 18;210(12):2627-39. doi: 10.1084/jem.20131144. Epub 2013 Nov 11.
35. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Ning X, etal., Cancer Lett. 2015 Apr 10;359(2):198-205. doi: 10.1016/j.canlet.2015.01.005. Epub 2015 Jan 13.
36. BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells. Nishioka C, etal., Leuk Res. 2016 Jun;45:24-32. doi: 10.1016/j.leukres.2016.03.012. Epub 2016 Apr 1.
37. Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer. Ohuchi M, etal., Oncol Lett. 2018 Oct;16(4):5275-5281. doi: 10.3892/ol.2018.9240. Epub 2018 Jul 31.
38. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
39. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Paolicchi E, etal., Oncol Lett. 2013 Nov;6(5):1487-1491. doi: 10.3892/ol.2013.1559. Epub 2013 Sep 2.
40. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
41. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
42. Inhibition of Histone Methyltransferase EZH2 Suppresses Endometriotic Vesicle Development in a Rat Model of Endometriosis. Seguinot-Tarafa I, etal., Reprod Sci. 2020 Sep;27(9):1812-1820. doi: 10.1007/s43032-020-00257-9. Epub 2020 Jul 10.
43. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration. Shiogama S, etal., Anticancer Res. 2013 Oct;33(10):4309-17.
44. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Simon C, etal., Genes Dev. 2012 Apr 1;26(7):651-6. doi: 10.1101/gad.186411.111. Epub 2012 Mar 19.
45. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Simon JA and Kingston RE, Mol Cell. 2013 Mar 7;49(5):808-24. doi: 10.1016/j.molcel.2013.02.013.
46. Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology. Su KJ, etal., Am J Cancer Res. 2015 Oct 15;5(11):3475-84. eCollection 2015.
47. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Takawa M, etal., Cancer Sci. 2011 Jul;102(7):1298-305. doi: 10.1111/j.1349-7006.2011.01958.x. Epub 2011 May 26.
48. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Tanaka S, etal., Blood. 2012 Aug 2;120(5):1107-17. doi: 10.1182/blood-2011-11-394932. Epub 2012 Jun 7.
49. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. van Leenders GJ, etal., Eur Urol. 2007 Aug;52(2):455-63. Epub 2006 Nov 17.
50. EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD. Vella S, etal., Int J Mol Sci. 2013 Dec 12;14(12):24154-68. doi: 10.3390/ijms141224154.
51. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients]. Wang HR, etal., Nan Fang Yi Ke Da Xue Xue Bao. 2015 Jan;35(1):99-102.
52. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Wang J, etal., Leuk Res. 2013 Mar;37(3):305-11. doi: 10.1016/j.leukres.2012.10.004. Epub 2012 Oct 23.
53. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma. Xie CR, etal., Oncotarget. 2015 Dec 1;6(38):40940-52. doi: 10.18632/oncotarget.5724.
54. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Xu F, etal., Ann Hematol. 2011 Jun;90(6):643-53. doi: 10.1007/s00277-010-1128-5. Epub 2010 Dec 2.
55. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. Xu L, etal., J Hepatol. 2014 Mar;60(3):590-8. doi: 10.1016/j.jhep.2013.10.028. Epub 2013 Nov 6.
56. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Yamada A, etal., Int J Oncol. 2011 Feb;38(2):345-53. doi: 10.3892/ijo.2010.868. Epub 2010 Dec 9.
57. MicroRNA-214 provokes cardiac hypertrophy via repression of EZH2. Yang T, etal., Biochem Biophys Res Commun. 2013 Jul 12;436(4):578-84. doi: 10.1016/j.bbrc.2013.05.079. Epub 2013 May 29.
58. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. Yoon KA, etal., J Thorac Oncol. 2010 Jan;5(1):10-6. doi: 10.1097/JTO.0b013e3181c422d9.
59. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Yoshida K, etal., Nat Genet. 2013 Nov;45(11):1293-9. doi: 10.1038/ng.2759. Epub 2013 Sep 22.
60. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma. Yu YL, etal., PLoS One. 2013 Sep 10;8(9):e74870. doi: 10.1371/journal.pone.0074870. eCollection 2013.
61. Aberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinoma. Zhang Y, etal., PLoS One. 2014 Sep 16;9(9):e107251. doi: 10.1371/journal.pone.0107251. eCollection 2014.
62. Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. Zhou J, etal., Nat Commun. 2019 Jun 3;10(1):2427. doi: 10.1038/s41467-019-10176-2.
63. EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population. Zhou Y, etal., Mol Carcinog. 2014 Aug;53(8):589-97. doi: 10.1002/mc.21871. Epub 2012 Jan 6.
Additional References at PubMed
PMID:9214638   PMID:9584197   PMID:12477932   PMID:12900441   PMID:15385962   PMID:15520282   PMID:16179254   PMID:16717091   PMID:18311137   PMID:18483221   PMID:18713946   PMID:19026781  
PMID:19144645   PMID:19303854   PMID:19734898   PMID:20064375   PMID:20064376   PMID:20075857   PMID:20144788   PMID:20154697   PMID:20798045   PMID:20808772   PMID:20956546   PMID:21123648  
PMID:21172659   PMID:21498568   PMID:21936910   PMID:22056776   PMID:22323599   PMID:22438827   PMID:22482507   PMID:22873822   PMID:22911650   PMID:22949634   PMID:23046516   PMID:23104054  
PMID:23160351   PMID:23273982   PMID:23942234   PMID:24105743   PMID:24137001   PMID:24474760   PMID:24623306   PMID:25380300   PMID:25477280   PMID:25547114   PMID:26423156   PMID:26658965  
PMID:26694085   PMID:27499068   PMID:27762633   PMID:28332284   PMID:28344045   PMID:28612962   PMID:29039454   PMID:29337251   PMID:30030400   PMID:30390343   PMID:30887911   PMID:31451685  
PMID:31511494   PMID:31608710   PMID:31907922   PMID:32054404   PMID:32346844   PMID:32933418   PMID:33391480   PMID:33803922   PMID:34020664   PMID:34104112   PMID:34668273   PMID:34789399  
PMID:35172677  


Genomics

Comparative Map Data
Ezh2
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2476,624,399 - 76,687,362 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl476,624,399 - 76,687,362 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx481,590,638 - 81,653,503 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0477,503,983 - 77,566,865 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0475,884,156 - 75,947,036 (-)NCBIRnor_WKY
Rnor_6.0477,284,404 - 77,347,011 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl477,284,404 - 77,347,011 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.04141,955,864 - 142,018,471 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4475,709,959 - 75,773,279 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera471,429,142 - 71,492,047 (-)NCBICelera
Cytogenetic Map4q24NCBI
EZH2
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh387148,807,383 - 148,884,291 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl7148,807,257 - 148,884,321 (-)EnsemblGRCh38hg38GRCh38
GRCh377148,504,475 - 148,581,383 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 367148,135,408 - 148,212,347 (-)NCBINCBI36Build 36hg18NCBI36
Build 347147,942,122 - 148,019,062NCBI
Celera7143,174,898 - 143,251,832 (-)NCBICelera
Cytogenetic Map7q36.1NCBI
HuRef7142,583,460 - 142,659,958 (-)NCBIHuRef
CHM1_17148,512,861 - 148,589,845 (-)NCBICHM1_1
T2T-CHM13v2.07149,989,157 - 150,066,070 (-)NCBIT2T-CHM13v2.0
CRA_TCAGchr7v27147,842,417 - 147,919,393 (-)NCBI
Ezh2
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39647,507,208 - 47,572,309 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl647,507,073 - 47,572,275 (-)EnsemblGRCm39 Ensembl
GRCm38647,530,274 - 47,595,270 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl647,530,139 - 47,595,341 (-)EnsemblGRCm38mm10GRCm38
MGSCv37647,480,273 - 47,545,029 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36647,459,867 - 47,524,606 (-)NCBIMGSCv36mm8
Celera647,385,379 - 47,451,063 (-)NCBICelera
Cytogenetic Map6B2.3NCBI
cM Map622.92NCBI
Ezh2
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554914,215,298 - 4,292,235 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554914,215,353 - 4,292,229 (-)NCBIChiLan1.0ChiLan1.0
EZH2
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.17153,017,590 - 153,059,726 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl7153,017,590 - 153,059,726 (-)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v07140,536,962 - 140,613,104 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
EZH2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1161,926,443 - 1,991,995 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl161,925,956 - 1,991,838 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha163,025,322 - 3,090,857 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0161,730,910 - 1,796,671 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl161,754,174 - 1,796,670 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1161,717,683 - 1,783,294 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0161,577,046 - 1,642,624 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0161,581,164 - 1,646,809 (+)NCBIUU_Cfam_GSD_1.0
Ezh2
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_0244051187,804,044 - 7,879,353 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365275,024,068 - 5,063,939 (-)EnsemblSpeTri2.0
SpeTri2.0NW_0049365275,024,077 - 5,069,152 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
EZH2
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl9109,385,015 - 109,450,941 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.19109,384,976 - 109,450,943 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.29120,322,804 - 120,388,754 (+)NCBISscrofa10.2Sscrofa10.2susScr3
EZH2
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.121117,380,518 - 117,515,224 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl21117,380,361 - 117,421,573 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366607213,330,068 - 13,407,159 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Ezh2
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046248006,802,901 - 6,874,196 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046248006,781,848 - 6,874,221 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Ezh2
141 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:76
Count of miRNA genes:64
Interacting mature miRNAs:72
Transcripts:ENSRNOT00000008149
Prediction methods:Miranda, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
619616Bp79Blood pressure QTL 790.0292arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)4521460278882945Rat
2303168Bp330Blood pressure QTL 3304.250.017arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)45214602146446691Rat
631261Tcas3Tongue tumor susceptibility QTL 36.88tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)41081417091360527Rat
2316958Gluco58Glucose level QTL 5810blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)411320076180699135Rat
8655906Rf60Renal function QTL 603.8blood creatinine amount (VT:0005328)creatinine clearance (CMO:0000765)42949419581006281Rat
12798520Anxrr55Anxiety related response QTL 554.450.01locomotor behavior trait (VT:0001392)number of rearing movements with lid-pushing in an experimental apparatus (CMO:0002715)432583980114627242Rat
8552782Vie1Viral induced encephalitis QTL 126.4brain integrity trait (VT:0010579)encephalitis incidence/prevalence measurement (CMO:0002361)43443048482490359Rat
8552801Bw143Body weight QTL 1437.3body mass (VT:0001259)change in body weight to body weight ratio (CMO:0002216)43443048482490359Rat
8552809Vie5Viral induced encephalitis QTL 525.3brain integrity trait (VT:0010579)encephalitis incidence/prevalence measurement (CMO:0002361)43443048482490359Rat
8655961Kidm43Kidney mass QTL 4318kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)436303261103194984Rat
1358352Srcrt3Stress Responsive Cort QTL 32.29blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)438465774146803430Rat
1300139Hrtrt6Heart rate QTL 62.85heart pumping trait (VT:2000009)heart rate (CMO:0000002)439524264116179656Rat
61445Strs3Sensitivity to stroke QTL 33cerebrum integrity trait (VT:0010549)post-insult time to onset of cerebrovascular lesion (CMO:0002343)44043338885433388Rat
8694439Bw168Body weight QTL 1689.570.001retroperitoneal fat pad mass (VT:0010430)retroperitoneal fat pad weight to body weight ratio (CMO:0000635)44043341485433414Rat
6893678Bw108Body weight QTL 1082.60.006body mass (VT:0001259)body weight (CMO:0000012)44345797688457976Rat
1576305Emca6Estrogen-induced mammary cancer QTL 65.8mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)444463720155883716Rat
1354612Foco1Food consumption QTL 18.87eating behavior trait (VT:0001431)food intake rate (CMO:0000427)444463908148090542Rat
1354660Salc1Saline consumption QTL 111.26drinking behavior trait (VT:0001422)saline drink intake rate (CMO:0001627)444463908148090542Rat
2312567Glom19Glomerulus QTL 191.90.006kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)445456990146803430Rat
1298082Stresp4Stress response QTL 4blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)450119848146803430Rat
4889969Bss96Bone structure and strength QTL 964.9tibia size trait (VT:0100001)tibia cortical bone volume (CMO:0001725)45664777678882945Rat
4889972Bss97Bone structure and strength QTL 975.6tibia size trait (VT:0100001)tibia total bone volume (CMO:0001724)45664777678882945Rat
5685009Bmd86Bone mineral density QTL 863.7tibia mineral mass (VT:1000283)bone mineral density (CMO:0001226)45664777678882945Rat
5685012Bmd87Bone mineral density QTL 875.1tibia mineral mass (VT:1000283)bone mineral content (CMO:0001554)45664777678882945Rat
70200Alc18Alcohol consumption QTL 189.2drinking behavior trait (VT:0001422)ethanol intake volume to total fluid intake volume ratio (CMO:0001591)456647873149491524Rat
1641833Alc21Alcohol consumption QTL 218.60.0001drinking behavior trait (VT:0001422)ethanol drink intake rate (CMO:0001407)456698790126192555Rat
631546Bp86Blood pressure QTL 863.2arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)45711443291360801Rat
634311Sach7Saccharin preference QTL 7taste sensitivity trait (VT:0001986)saccharin intake volume to total fluid intake volume ratio (CMO:0001601)457114432102114432Rat
61336Bp21Blood pressure QTL 214.6arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)45711470578881294Rat
1358363Sradr3Stress Responsive Adrenal Weight QTL 36.19adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)457486946102486946Rat
1558651Swd3Spike wave discharge measurement QTL 34.620.000024brain electrophysiology trait (VT:0010557)brain spike-and-wave discharge frequency (CMO:0001742)45843213392991462Rat
631671Iddm11Insulin dependent diabetes mellitus QTL 113.60.0012blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)45863587778886137Rat
738009Sach4Saccharine consumption QTL 44.90.000016consumption behavior trait (VT:0002069)saccharin intake volume to total fluid intake volume ratio (CMO:0001601)459948935154902892Rat
738016Alc16Alcohol consumption QTL 163.60.00015consumption behavior trait (VT:0002069)ethanol drink intake rate to body weight ratio (CMO:0001616)459948935154902892Rat
738031Alc14Alcohol consumption QTL 147.60.00003consumption behavior trait (VT:0002069)ethanol drink intake rate to body weight ratio (CMO:0001616)459948935154902892Rat
1578657Bss12Bone structure and strength QTL 128.9femur morphology trait (VT:0000559)femoral neck cross-sectional area (CMO:0001697)460220938105220938Rat
1578658Bss13Bone structure and strength QTL 138femur strength trait (VT:0010010)femoral neck polar moment of inertia (CMO:0001670)460220938105220938Rat
2300179Bmd50Bone mineral density QTL 505.90.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)460928534105928534Rat
1549843Bw53Body weight QTL 530.0001body mass (VT:0001259)body weight gain (CMO:0000420)461697658103194791Rat
1549839Bw52Body weight QTL 520.0001body mass (VT:0001259)body weight gain (CMO:0000420)461697658115089733Rat
61418Pia5Pristane induced arthritis QTL 54.5joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)462277855128289560Rat
6478743Anxrr40Anxiety related response QTL 400.83076defecation behavior trait (VT:0010462)defecation rate (CMO:0000998)462753847107753847Rat
6478772Anxrr49Anxiety related response QTL 490.15488defecation behavior trait (VT:0010462)defecation rate (CMO:0000998)462753847107753847Rat
6478684Anxrr30Anxiety related response QTL 300.00087defecation behavior trait (VT:0010462)defecation rate (CMO:0000998)462753847107753847Rat
631651Bp124Blood pressure QTL 1243arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)462879517107879517Rat
7394826Bw126Body weight QTL 1260.002body mass (VT:0001259)body weight gain (CMO:0000420)46293326987483707Rat
8552807Vie4Viral induced encephalitis QTL 47.3brain integrity trait (VT:0010579)encephalitis incidence/prevalence measurement (CMO:0002361)46293350882490359Rat
70192BpQTLcluster5Blood pressure QTL cluster 54.183arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)462933508114921294Rat
70192BpQTLcluster5Blood pressure QTL cluster 54.183arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)462933508114921294Rat
70192BpQTLcluster5Blood pressure QTL cluster 54.183arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)462933508114921294Rat
70192BpQTLcluster5Blood pressure QTL cluster 54.183arterial blood pressure trait (VT:2000000)percent change in mean arterial blood pressure (CMO:0002035)462933508114921294Rat
70192BpQTLcluster5Blood pressure QTL cluster 54.183arterial blood pressure trait (VT:2000000)percent change in systolic blood pressure (CMO:0000747)462933508114921294Rat
70192BpQTLcluster5Blood pressure QTL cluster 54.183arterial blood pressure trait (VT:2000000)absolute change in pulse pressure (CMO:0001882)462933508114921294Rat
70192BpQTLcluster5Blood pressure QTL cluster 54.183arterial blood pressure trait (VT:2000000)absolute change in mean arterial blood pressure (CMO:0000533)462933508114921294Rat
631674Iddm14Insulin dependent diabetes mellitus QTL 14blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)464528739157573521Rat
2312569Pur19Proteinuria QTL 193.40.001urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)46588210796130297Rat
61330Eau1Experimental allergic uveoretinitis QTL 10.0003uvea integrity trait (VT:0010551)experimental autoimmune uveitis score (CMO:0001504)470362013132642728Rat
634344Hcar7Hepatocarcinoma resistance QTL 77.8liver integrity trait (VT:0010547)liver tumorous lesion area to total liver area ratio (CMO:0001075)470808386115808386Rat
634344Hcar7Hepatocarcinoma resistance QTL 77.8liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)470808386115808386Rat
631646Stl4Serum triglyceride level QTL 46.50.0001blood triglyceride amount (VT:0002644)plasma triglyceride level (CMO:0000548)473169846132642728Rat
724522Bp146Blood pressure QTL 1462.20.0021arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)473630210118630210Rat
2302051Pia28Pristane induced arthritis QTL 285.30.001blood autoantibody amount (VT:0003725)serum immunoglobulin G-type rheumatoid factor level relative to an arbitrary reference serum (CMO:0002112)473630210118630210Rat
70167Bw22Body weight QTL 223.1body mass (VT:0001259)body weight (CMO:0000012)476647384117676292Rat
1357342Bw40Body weight QTL 400.001body mass (VT:0001259)body weight (CMO:0000012)476647384117676292Rat

Markers in Region
D4Mit6  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2476,647,384 - 76,647,568 (+)MAPPERmRatBN7.2
Rnor_6.0477,307,388 - 77,307,571NCBIRnor6.0
Rnor_5.04141,978,848 - 141,979,031UniSTSRnor5.0
RGSC_v3.4475,732,943 - 75,733,127RGDRGSC3.4
RGSC_v3.4475,732,944 - 75,733,127UniSTSRGSC3.4
Celera471,452,122 - 71,452,305UniSTS
Cytogenetic Map4q24UniSTS
D4Got210  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2476,680,416 - 76,680,712 (+)MAPPERmRatBN7.2
Rnor_6.0477,339,806 - 77,340,101NCBIRnor6.0
Rnor_5.04142,011,266 - 142,011,561UniSTSRnor5.0
RGSC_v3.4475,766,334 - 75,766,629UniSTSRGSC3.4
Celera471,485,098 - 71,485,395UniSTS
Cytogenetic Map4q24UniSTS
Ezh2  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2476,624,613 - 76,624,740 (+)MAPPERmRatBN7.2
Rnor_6.0477,284,619 - 77,284,745NCBIRnor6.0
Rnor_5.04141,956,079 - 141,956,205UniSTSRnor5.0
RGSC_v3.4475,710,174 - 75,710,300UniSTSRGSC3.4
Celera471,429,357 - 71,429,483UniSTS
Cytogenetic Map4q24UniSTS
U52951  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2476,624,590 - 76,624,743 (+)MAPPERmRatBN7.2
Rnor_6.0477,284,596 - 77,284,748NCBIRnor6.0
Rnor_5.04141,956,056 - 141,956,208UniSTSRnor5.0
RGSC_v3.4475,710,151 - 75,710,303UniSTSRGSC3.4
Celera471,429,334 - 71,429,486UniSTS
Cytogenetic Map4q24UniSTS
UniSTS:143054  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2476,636,914 - 76,637,128 (+)MAPPERmRatBN7.2
Rnor_6.0477,296,919 - 77,297,132NCBIRnor6.0
Rnor_5.04141,968,379 - 141,968,592UniSTSRnor5.0
RGSC_v3.4475,722,475 - 75,722,688UniSTSRGSC3.4
Celera471,441,658 - 71,441,871UniSTS
Cytogenetic Map4q24UniSTS
RH125972  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2476,678,695 - 76,678,890 (+)MAPPERmRatBN7.2
Rnor_6.0477,338,085 - 77,338,279NCBIRnor6.0
Rnor_5.04142,009,545 - 142,009,739UniSTSRnor5.0
RGSC_v3.4475,764,613 - 75,764,807UniSTSRGSC3.4
Celera471,483,377 - 71,483,571UniSTS
Cytogenetic Map4q24UniSTS
PMC87093P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2476,645,485 - 76,645,889 (+)MAPPERmRatBN7.2
Rnor_6.0477,305,489 - 77,305,892NCBIRnor6.0
Rnor_5.04141,976,949 - 141,977,352UniSTSRnor5.0
RGSC_v3.4475,731,045 - 75,731,448UniSTSRGSC3.4
Celera471,450,223 - 71,450,626UniSTS
Cytogenetic Map4q24UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 26 33 22 19 22 53 22 40 11
Low 17 24 19 19 8 11 21 13 1 8
Below cutoff

Sequence

Nucleotide Sequences
RefSeq Transcripts NM_001134979 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_006236401 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_006236402 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_006236403 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_006236404 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_006236405 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_006236406 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_006236408 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_008762884 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039107530 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039107532 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039107533 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039107534 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  XM_039107535 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
GenBank Nucleotide BC169027 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  CH473959 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  FQ230311 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  JACYVU010000141 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles

Reference Sequences
RefSeq Acc Id: ENSRNOT00000008149   ⟹   ENSRNOP00000008149
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl476,624,399 - 76,687,362 (-)Ensembl
Rnor_6.0 Ensembl477,284,404 - 77,347,011 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000103771   ⟹   ENSRNOP00000083073
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl476,624,399 - 76,687,362 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000107831   ⟹   ENSRNOP00000091329
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl476,624,399 - 76,687,362 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000112850   ⟹   ENSRNOP00000078960
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl476,624,399 - 76,687,362 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000115043   ⟹   ENSRNOP00000092431
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl476,624,541 - 76,687,153 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000119927   ⟹   ENSRNOP00000088670
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl476,654,110 - 76,687,362 (-)Ensembl
RefSeq Acc Id: NM_001134979   ⟹   NP_001128451
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,399 - 76,687,362 (-)NCBI
Rnor_6.0477,284,404 - 77,347,011 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
RGSC_v3.4475,709,959 - 75,773,279 (-)RGD
Celera471,429,142 - 71,492,047 (-)RGD
Sequence:
RefSeq Acc Id: XM_006236401   ⟹   XP_006236463
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,540 - 76,687,360 (-)NCBI
Rnor_6.0477,284,550 - 77,347,009 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
Sequence:
RefSeq Acc Id: XM_006236402   ⟹   XP_006236464
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,540 - 76,687,356 (-)NCBI
Rnor_6.0477,284,550 - 77,347,009 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
Sequence:
RefSeq Acc Id: XM_006236403   ⟹   XP_006236465
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,687,360 (-)NCBI
Rnor_6.0477,284,550 - 77,347,008 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
Sequence:
RefSeq Acc Id: XM_006236404   ⟹   XP_006236466
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,687,360 (-)NCBI
Rnor_6.0477,284,550 - 77,347,009 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
Sequence:
RefSeq Acc Id: XM_006236405   ⟹   XP_006236467
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,687,356 (-)NCBI
Rnor_6.0477,284,550 - 77,347,009 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
Sequence:
RefSeq Acc Id: XM_006236406   ⟹   XP_006236468
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,687,360 (-)NCBI
Rnor_6.0477,284,550 - 77,347,008 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
Sequence:
RefSeq Acc Id: XM_006236408   ⟹   XP_006236470
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,687,360 (-)NCBI
Rnor_6.0477,284,550 - 77,347,008 (-)NCBI
Rnor_5.04141,955,864 - 142,018,471 (-)NCBI
Sequence:
RefSeq Acc Id: XM_008762884   ⟹   XP_008761106
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,687,360 (-)NCBI
Rnor_6.0477,284,550 - 77,347,009 (-)NCBI
Sequence:
RefSeq Acc Id: XM_039107530   ⟹   XP_038963458
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,540 - 76,686,704 (-)NCBI
RefSeq Acc Id: XM_039107532   ⟹   XP_038963460
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,670,070 (-)NCBI
RefSeq Acc Id: XM_039107533   ⟹   XP_038963461
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,670,066 (-)NCBI
RefSeq Acc Id: XM_039107534   ⟹   XP_038963462
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,670,025 (-)NCBI
RefSeq Acc Id: XM_039107535   ⟹   XP_038963463
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2476,624,546 - 76,670,025 (-)NCBI
Reference Sequences
RefSeq Acc Id: NP_001128451   ⟸   NM_001134979
- UniProtKB: B5DFE2 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006236467   ⟸   XM_006236405
- Peptide Label: isoform X3
- Sequence:
RefSeq Acc Id: XP_006236464   ⟸   XM_006236402
- Peptide Label: isoform X1
- Sequence:
RefSeq Acc Id: XP_006236466   ⟸   XM_006236404
- Peptide Label: isoform X3
- Sequence:
RefSeq Acc Id: XP_006236463   ⟸   XM_006236401
- Peptide Label: isoform X1
- Sequence:
RefSeq Acc Id: XP_006236468   ⟸   XM_006236406
- Peptide Label: isoform X4
- Sequence:
RefSeq Acc Id: XP_006236465   ⟸   XM_006236403
- Peptide Label: isoform X2
- UniProtKB: B5DFE2 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006236470   ⟸   XM_006236408
- Peptide Label: isoform X6
- Sequence:
RefSeq Acc Id: XP_008761106   ⟸   XM_008762884
- Peptide Label: isoform X5
- Sequence:
RefSeq Acc Id: ENSRNOP00000008149   ⟸   ENSRNOT00000008149
RefSeq Acc Id: XP_038963458   ⟸   XM_039107530
- Peptide Label: isoform X1
RefSeq Acc Id: XP_038963460   ⟸   XM_039107532
- Peptide Label: isoform X7
RefSeq Acc Id: XP_038963461   ⟸   XM_039107533
- Peptide Label: isoform X7
RefSeq Acc Id: XP_038963463   ⟸   XM_039107535
- Peptide Label: isoform X9
RefSeq Acc Id: XP_038963462   ⟸   XM_039107534
- Peptide Label: isoform X8
RefSeq Acc Id: ENSRNOP00000088670   ⟸   ENSRNOT00000119927
RefSeq Acc Id: ENSRNOP00000091329   ⟸   ENSRNOT00000107831
RefSeq Acc Id: ENSRNOP00000083073   ⟸   ENSRNOT00000103771
RefSeq Acc Id: ENSRNOP00000078960   ⟸   ENSRNOT00000112850
RefSeq Acc Id: ENSRNOP00000092431   ⟸   ENSRNOT00000115043
Protein Domains
CXC   SET

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-B5DFE2-F1-model_v2 AlphaFold B5DFE2 1-746 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13693019
Promoter ID:EPDNEW_R3542
Type:initiation region
Name:Ezh2_1
Description:enhancer of zeste 2 polycomb repressive complex 2 subunit
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0477,346,953 - 77,347,013EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:1595860 AgrOrtholog
BioCyc Gene G2FUF-45011 BioCyc
Ensembl Genes ENSRNOG00000006048 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000008149 ENTREZGENE
  ENSRNOP00000008149.4 UniProtKB/TrEMBL
  ENSRNOP00000078960.1 UniProtKB/TrEMBL
  ENSRNOP00000083073.1 UniProtKB/TrEMBL
  ENSRNOP00000088670.1 UniProtKB/TrEMBL
  ENSRNOP00000091329.1 UniProtKB/TrEMBL
  ENSRNOP00000092431 ENTREZGENE
  ENSRNOP00000092431.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000008149 ENTREZGENE
  ENSRNOT00000008149.6 UniProtKB/TrEMBL
  ENSRNOT00000103771.1 UniProtKB/TrEMBL
  ENSRNOT00000107831.1 UniProtKB/TrEMBL
  ENSRNOT00000112850.1 UniProtKB/TrEMBL
  ENSRNOT00000115043 ENTREZGENE
  ENSRNOT00000115043.1 UniProtKB/TrEMBL
  ENSRNOT00000119927.1 UniProtKB/TrEMBL
Gene3D-CATH 2.170.270.10 UniProtKB/TrEMBL
InterPro CXC_dom UniProtKB/TrEMBL
  EZH1/2-like UniProtKB/TrEMBL
  EZH2_SET UniProtKB/TrEMBL
  EZH2_WD-Binding UniProtKB/TrEMBL
  Homeobox-like_sf UniProtKB/TrEMBL
  PRC2_HTH_1 UniProtKB/TrEMBL
  Pre-SET_CXC UniProtKB/TrEMBL
  SANT_DNA-bd UniProtKB/TrEMBL
  SET_dom UniProtKB/TrEMBL
  SET_dom_sf UniProtKB/TrEMBL
  Tesmin/TSO1-like_CXC UniProtKB/TrEMBL
KEGG Report rno:312299 UniProtKB/TrEMBL
NCBI Gene 312299 ENTREZGENE
PANTHER PTHR45747 UniProtKB/TrEMBL
Pfam EZH2_WD-Binding UniProtKB/TrEMBL
  PRC2_HTH_1 UniProtKB/TrEMBL
  preSET_CXC UniProtKB/TrEMBL
  SET UniProtKB/TrEMBL
PhenoGen Ezh2 PhenoGen
PROSITE CXC UniProtKB/TrEMBL
  SET UniProtKB/TrEMBL
SMART CXC UniProtKB/TrEMBL
  SANT UniProtKB/TrEMBL
  SET UniProtKB/TrEMBL
Superfamily-SCOP SSF46689 UniProtKB/TrEMBL
  SSF82199 UniProtKB/TrEMBL
UniProt A0A8I5ZPT6_RAT UniProtKB/TrEMBL
  A0A8I6A8A9_RAT UniProtKB/TrEMBL
  A0A8I6AHI4_RAT UniProtKB/TrEMBL
  A0A8I6GAA5_RAT UniProtKB/TrEMBL
  A0A8I6GJI6_RAT UniProtKB/TrEMBL
  B5DFE2 ENTREZGENE, UniProtKB/TrEMBL


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2014-06-06 Ezh2  enhancer of zeste 2 polycomb repressive complex 2 subunit  Ezh2  enhancer of zeste homolog 2 (Drosophila)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-03-05 Ezh2  enhancer of zeste homolog 2 (Drosophila)  LOC312299  similar to Enhancer of zeste homolog 2 (ENX-1)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2006-11-20 LOC312299  similar to Enhancer of zeste homolog 2 (ENX-1)      Symbol and Name status set to provisional 70820 PROVISIONAL